Market Access How can biotech survive its funding winter? Some may argue that VCs and public markets have turned against biotech, but the reality is they have become much more sceptical.
News Oxford BioMedica confirms private equity takeover talks Oxford BioMedica confirmed this morning that it has received an unsolicited approach from private equity group EQT about a possible takeover.
News Hippocratic AI builds in life sciences with Grove AI buy Hippocratic AI has expanded with the acquisition of Grove AI, a specialist in AI used in pharma R&D, building on its patient-facing GenAI agents.
News Abivax climbs on Lilly takeover speculation Shares in Abivax were tracking up this morning as a media report in France suggested it could see a €15bn takeover offer from Eli Lilly.
News Report says MSD is in talks to buy Revolution Meds MSD is rumoured to be in talks to buy Revolution Medicines and its KRAS inhibitor pipeline in a deal that could be worth up to $32 billion.
News Rumour confirmed as Lilly buys Ventyx for $1.2 billion Eli Lilly has agreed a $1.2bn takeover of Ventyx Bio and its clinical-stage drugs for inflammatory and cardiometabolic diseases.
News NHS to offer Wegovy to a million more people in England The NHS in England will make Novo Nordisk's Wegovy available to around 1.2m people in order to reduce their risk of heart attacks and strokes.
Sales & Marketing Sponsored Using AI-driven synthetic personas to take your insights fur... As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.
